Abstract
Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer. However, complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy.
Original language | English (US) |
---|---|
Article number | 18 |
Journal | Journal of Hematology and Oncology |
Volume | 1 |
Issue number | 1 |
DOIs | |
State | Published - 2008 |
ASJC Scopus subject areas
- Molecular Biology
- Hematology
- Oncology
- Cancer Research